SCHEMBL47583

SCHEMBL47583

CC(C)(C)C(=S)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14547635 0.71 TSHR (0.33)
SCHEMBL1196753 0.70
SCHEMBL9021930 0.70
SCHEMBL28291376 0.67
SCHEMBL15421170 0.67
SCHEMBL1026012 0.67
SCHEMBL7699149 0.67
SCHEMBL10653217 0.67
Potassium Ion SCHEMBL10765420 0.64
SCHEMBL16627914 0.61 MEN1 (0.37) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611166-B1 BUILDING SEALANT COMPOSITION BRIDGESTONE CORP (JP) 2007-08-29 EP claimed
US-20240071772-A1 SUBSTRATE PROCESSING METHOD AND SUBSTRATE PROCESSING APPARATUS TOKYO ELECTRON LIMITED (JP) 2024-02-29 US disclosed
CN-117099188-A Substrate processing method and substrate processing apparatus 东京毅力科创株式会社 2023-11-21 CN disclosed
US-20230339947-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS Madera Therapeutics, LLC 2023-10-26 US disclosed
US-11766442-B2 T-cell lymphoma treatments CITY OF HOPE (US) 2023-09-26 US disclosed
US-20230147962-A1 FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS PHILOCHEM AG (CH) 2023-05-11 US disclosed
WO-2022211057-A1 SUBSTRATE PROCESSING METHOD AND SUBSTRATE PROCESSING DEVICE 東京エレクトロン株式会社 2022-10-06 WO disclosed
US-11328933-B2 Etching method, substrate processing apparatus, and substrate processing system TOKYO ELECTRON LIMITED (JP) 2022-05-10 US disclosed
US-20210202260-A1 ETCHING METHOD, SUBSTRATE PROCESSING APPARATUS, AND SUBSTRATE PROCESSING SYSTEM TOKYO ELECTRON LIMITED (JP) 2021-07-01 US disclosed
US-10822353-B2 Dithio ETP derivatives CITY OF HOPE (US) 2020-11-03 US disclosed
US-20080020127-A1 Methods and systems for coating a medical device ALLACCEM, INC. 2008-01-24 US disclosed
US-20070202342-A1 Applying to an oral surface (teeth or gums)one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning; dentistry; bonding agents, resin cements, sealants ALLACCEM, INC. 2007-08-30 US disclosed
EP-1497268-A4 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2006-01-18 EP disclosed
EP-1497268-A2 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-01-19 EP disclosed
US-20030203915-A1 Nitric oxide donors, compositions and methods of use related applications NICOX S.A. (FR) 2003-10-30 US disclosed
WO-2003086282-A2 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2003-10-23 WO disclosed
EP-0479561-B1 Process for heat-treating a polyolefin coating on metal in the presence of a treating agent MITSUI PETROCHEMICAL IND (JP) 1995-08-23 EP disclosed
US-5275848-A Process for preparing a laminate of metal and a polyolefin resin MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1994-01-04 US disclosed
EP-0479561-A2 Process for heat-treating a polyolefin coating on metal in the presence of a treating agent MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-04-08 EP disclosed
US-4370497-A Oxidation process using tellurium oxide catalysts BARTON DEREK H R (FR) 1983-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10822353-B2 Dithio ETP derivatives ETV1, ETV6, DLD MEN1 4110/4885KMT2A 2831/4885
US-20230339947-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS CLPP, PRCP, PREP MEN1 4322/4885KMT2A 4528/4885
US-20230147962-A1 FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS FAP, FIBP, FGFR1 MEN1 3505/4885KMT2A 4381/4885
US-11766442-B2 T-cell lymphoma treatments MALT1, BCL6, BCL3 MEN1 1496/4885KMT2A 857/4885
US-20030203915-A1 Nitric oxide donors, compositions and methods of use related applications NOS1, NOS2, NOS3 MEN1 3465/4885KMT2A 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.